Patent 8188224 was granted and assigned to Savient Pharmaceuticals, Inc. on May, 2012 by the United States Patent and Trademark Office.
Genetically modified proteins with uricolytic activity are described. Proteins comprising truncated urate oxidases and methods for producing them, including PEGylated proteins comprising truncated urate oxidase are described.